Related Experiment Video
Updated: Jun 3, 2025
07:21
Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
Published on: September 28, 2015
37.2K
Complex of Angiotensin II with Modified Low-Density Lipoproteins: Behavioral and Hemodynamic Effects in Rats
S M Tolpygo1, B B Shoibonov2, T S Zamolodchikova2
1Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies, Moscow, Russia. olpygo_sm@academpharm.ru.
Bulletin of Experimental Biology and Medicine
|January 6, 2025
Summary
Modified low-density lipoprotein (mLDL) and the renin-angiotensin system are key in atherosclerosis. Angiotensin II (Ang II) combined with mLDL alters its effects, potentially driving disease progression.
Area of Science:
- Cardiovascular Science
- Pathophysiology
- Biochemistry
Background:
- Multiple modified low-density lipoprotein (mLDL) and the renin-angiotensin system are implicated in atherosclerosis development.
- Angiotensin II (Ang II) activity is significantly altered by mLDL, affecting its diuretic, hypertensive, and tachyarrhythmic properties.
Purpose of the Study:
- To investigate the role of angiotensin complexes with mLDL in the early and progressive stages of atherosclerosis.
- To model the initial interaction of the body with pathogenic factors using synthesized Ang I-mLDL complexes.
Main Methods:
- Analysis of behavioral and hemodynamic parameters.
- Synthesis of artificial angiotensin I-mLDL complexes to model initial pathogenic factor exposure.
Main Results:
- Observed modification of Ang II's physiological activity, including weakened diuretic effects and inverted hypertensive/tachyarrhythmic effects when combined with mLDL.
- Angiotensin-mLDL complexes may act as a model for the initial encounter with atherosclerosis-promoting factors.
Conclusions:
- Angiotensin complexes with mLDL are proposed to be involved in adaptive and compensatory mechanisms during early atherosclerosis.
- These complexes may subsequently contribute to the progression of atherosclerosis.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
472
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
472
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
579
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
579
01:25Antihypertensive Drugs: Direct Renin Inhibitors
484
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
484
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
381
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
381
01:17Hormonal Regulation of Blood Pressure
2.4K
Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
2.4K
01:17Antihypertensive Drugs: Action of β1 Blockers
306
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
306